Can You Take BPC-157 With a GLP-1?

The Short Answer

You are four months into a GLP-1. The weight is moving. But your shoulder has been aching since long before any of this started, or your gut has been unhappy for years, and you have read enough about BPC-157 Explore PeRxBPC-157The Body Protection CompoundView peptide to wonder whether adding it is a problem.

Here is the version nobody selling BPC-157 will give you. There is no documented pharmacological interaction between BPC-157 and semaglutide or tirzepatide. There is also no human study that has given people both and watched what happened. Both statements are true at the same time, and the second one is the one that should shape how you think about this.

"No known interaction" is a statement about the published literature. It is not a statement about your body. It means nobody has reported a problem. It does not mean anyone has gone looking.

What "No Known Interaction" Means

It helps to see what a real answer to a drug interaction question looks like, so you can measure the gap.

When the manufacturer of oral semaglutide needed to know whether it changed the absorption of four common medications, it ran two crossover trials in 84 healthy volunteers. Lisinopril, warfarin, digoxin, metformin. Exposure to the first three was unchanged. Metformin area under the curve rose 32 percent, which the authors judged not clinically relevant given metformin’s wide therapeutic index. Published, peer reviewed, with confidence intervals attached.

Bækdal TA et al., "Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects," Clinical Pharmacokinetics, 2019; 58(9): 1193-1203. View study

That is what it looks like when someone actually answers the question. Volunteers, a crossover design, plasma concentration curves, a number.

No study of that design has ever been run for BPC-157. Not against GLP-1 medications, not against anticoagulants, not against anything. The peptide has been in the literature since 1993 and its human pharmacokinetics still have not been characterized. There is no absorption curve, no half-life in people, no clearance data to model an interaction against even in theory.

What the BPC-157 Evidence Actually Is

A 2025 systematic review in HSS Journal searched PubMed, Cochrane, and Embase for everything published on BPC-157 from 1993 through June 2024. It identified 544 articles and included 36 after screening. Thirty-five were preclinical. One was clinical, and it was retrospective.

Vasireddi N et al., "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review," HSS Journal, 2025; 21(4): 485-495. View study

That is not a dismissal of the compound. The preclinical work is unusually consistent for a peptide with this much hype attached to it. BPC-157 promotes new blood vessel growth through VEGFR2 activation and upregulation in cell and rodent models. It drives tendon cell outgrowth, survival, and migration in cultured explants and fibroblast assays. Across animal models of muscle, tendon, ligament, and bone injury, treated tissue comes out with better functional, structural, and biomechanical outcomes than untreated tissue. Multiple labs, three decades, a repeatable signal. That is worth something, and our complete BPC-157 guide Read nextBPC-157: The Complete Guide to the Body Protection CompoundA peptide discovered in a Croatian lab in the early '90s is now one of the most studied healing compounds in regenerative medicine. Here's what the science actually says, where it came from, and what you should know before starting.Read article goes through the mechanism in detail.

Hsieh MJ et al., "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation," Journal of Molecular Medicine, 2017. Cell and rodent models. View study

Chang CH et al., "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration," Journal of Applied Physiology, 2011. Ex vivo tendon explants and cultured fibroblasts. View study

The human data is thin enough to describe in two sentences. A 2021 retrospective series reported durable relief in most patients after intra-articular BPC-157 injection for knee pain. A 2025 pilot gave intravenous BPC-157 to two adults and found no measurable change in cardiac, hepatic, renal, thyroid, or blood glucose biomarkers.

Lee E, Padgett B, "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain," Alternative Therapies in Health and Medicine, 2021. Lee E, Burgess K, "Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study," Alternative Therapies in Health and Medicine, 2025; 31(5): 20-24. View study

Two adults. That is a real study, conducted under IRB approval, and it is also, by any honest standard, a very small one. It is a reasonable first step. It is not a safety dataset, and it certainly is not a dataset about what happens when a third variable like a GLP-1 is added.

The One Interaction Worth Thinking About

If there is a plausible interaction here, it does not run the direction most people assume. It is not the peptide doing something to the GLP-1. It is the GLP-1 changing the conditions under which the peptide is absorbed, and it applies to only one of the two BPC-157 formats.

GLP-1 receptor agonists slow gastric emptying. This is not a footnote, it is part of the mechanism, and the size of the delay varies substantially between individuals. A 2024 Personal View in Lancet Gastroenterology and Hepatology walks through the physiology and how poorly the variation is currently predicted.

Jalleh RJ et al., "Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions," Lancet Gastroenterology and Hepatology, 2024; 9(10): 957-964. View study

Anything you swallow now sits in a stomach that empties more slowly than it used to. For established oral medications this is usually manageable, which is exactly why the semaglutide interaction study above exists and why lisinopril, warfarin, and digoxin came back clean. Those drugs have decades of absorption data behind them. BPC-157 capsules have none.

BPC-157 is unusual among peptides in that swallowing it is not obviously pointless. It was isolated from gastric juice and is comparatively stable in stomach acid, which is why oral capsules exist at all. That same property is why the gastric emptying question is not purely academic here. Nobody has measured what a markedly slowed stomach does to the absorption of oral BPC-157, because nobody has measured its absorption in humans under normal conditions either.

Subcutaneous injection sidesteps the question entirely. Injected BPC-157 never passes through the stomach, so gastric emptying is irrelevant to it. If you want the mechanics of subcutaneous dosing while already injecting weekly, where to inject semaglutide and tirzepatide Read nextWhere to Inject Semaglutide and TirzepatideBoth are once-weekly subcutaneous injections, and the three standard sites are the same for each. The part that trips people up is not the site. It is that a compounded vial is not a prefilled pen, so you are drawing your own dose and reading it in syringe units. Here is the practical version.Read article covers the site and rotation logic, which is the same logic that applies to a daily peptide.

Nausea Is a Different Problem

Many people arrive at this question sideways. They are a few weeks into a GLP-1, they feel queasy and constipated and generally unwell in the middle, they read that BPC-157 heals the gut, and the two ideas snap together.

They should not. The gut research on BPC-157 is about tissue damage. Gastric ulcers. Mucosal lesions. Injury from long-term anti-inflammatory drug use. Colitis models. Damaged lining in, healed lining out. That is the axis it operates on in the preclinical literature.

GLP-1 nausea is not tissue damage. It is a motility and signaling effect. The drug slows the stomach and acts on central pathways that govern appetite and nausea, and the lining underneath is intact the whole time. There is nothing structurally broken, so a compound whose evidence is about repairing broken structure has no obvious place to act.

This distinction is worth more than it sounds. The failure mode is not "BPC-157 does nothing." It is spending real money adding an unstudied compound to a regimen in order to solve a problem it was never plausibly going to solve, while the things that do tend to help go untried. Our GLP-1 nausea and gut side effects Read nextNausea & Gut Issues on GLP-1s 2026: What Actually HelpsGI side effects are the single biggest reason patients stop Ozempic, Wegovy, and Mounjaro. Why they happen, which simple changes resolve most cases, and when BPC-157 is the right add-on.Read article guide covers those.

The Muscle Loss Question

The other common route to this question is body composition. Weight lost on a GLP-1 includes lean mass along with fat, people read about that, and they start looking for something to hold the line.

BPC-157 is not that something. It is not an anabolic compound. It does upregulate growth hormone receptor expression in tendon fibroblasts, which sounds relevant and is not: that is a local repair signal at an injury site, not a systemic effect on muscle protein synthesis. No study has ever tested BPC-157 as a lean-mass-preservation agent in anyone losing weight, on a GLP-1 or otherwise. What it has data for is repair of injured connective tissue. That is a genuinely different job.

If lean mass is the actual concern, muscle loss on a GLP-1 Read nextHow to Keep Muscle While Taking Ozempic, Wegovy, or MounjaroUp to 40% of weight lost on GLP-1 medications is lean muscle. Here is what the research actually shows, why it happens, and which growth hormone peptides providers prescribe to preserve lean mass during a caloric deficit.Read article covers what the evidence supports, and most of the answer is resistance training and protein intake rather than any injectable.

Two Kinds of Not-FDA-Approved

People flatten these into one category. They are not the same, and the difference is worth understanding before you decide what to believe about either.

Semaglutide and tirzepatide exist inside FDA-approved products. Ozempic and Wegovy are semaglutide; Mounjaro and Zepbound are tirzepatide. Those went through the full approval process, and the clinical trial data attached to them belongs to those specific products. A compounded version of the same molecule is a different thing: it is prepared by a licensed pharmacy against an individual prescription, it has not been through FDA review for safety or effectiveness, and research conducted on the approved products is not evidence about a compounded preparation. Any page that quotes brand trial numbers while pointing you toward a compounded product is telling you something the data does not actually say.

BPC-157 is not-approved in a different way. There is no approved BPC-157 product at all, from anyone, for any indication. Its regulatory position has moved recently and is worth stating precisely: the FDA placed bulk BPC-157 in its restricted Category 2 list in 2023 and removed it in April 2026, and in July 2026 the agency’s Pharmacy Compounding Advisory Committee recommended it for the 503A bulks list in an 8-6 vote. It has not been added to that list. So it currently sits in a gray zone. No longer restricted, not yet cleared for routine compounding, and not FDA-approved.

If You Get Drug Tested

WADA lists BPC-157 under category S0, non-approved substances, which means it is prohibited at all times, in and out of competition. That covers anyone competing under a WADA-affiliated code, and the major North American leagues prohibit it as well.

Whether your GLP-1 raises a separate issue depends on your sport and whether a therapeutic use exemption is in place, which is a question for your governing body rather than anything a blog can settle. The BPC-157 part is not ambiguous. For a tested athlete it is disqualifying on its own, regardless of what else is in the picture.

How to Actually Decide

If you read this far hoping for a clean yes or no, here is the closest thing that exists.

Nothing in the literature suggests these two collide. Thirty years of BPC-157 research has not produced a signal of dangerous interactions with anything, and that is genuinely worth something. What is missing is the affirmative evidence that would let anyone say the combination has been studied and found safe, and no amount of confident writing on the internet manufactures that.

So the reasonable posture is a short list. Put BPC-157 on the medication list you hand to whoever prescribes your GLP-1. People routinely leave peptides off that list because they think of them as supplements, and they are not. Do not start both in the same week. Starting two new things at once makes it impossible to attribute anything that follows, which is a general principle of medicine and not a peptide-specific one. Be clear about why you want it. A nagging tendon, an old joint injury, a diagnosed GI condition: those are the things BPC-157 has preclinical data for. "GLP-1 side effects" is not on that list. And get it prescribed rather than ordered, which is the difference between a compound dispensed by a licensed pharmacy against a prescription and a vial from a site that legally cannot tell you what to do with it.

Common Questions